作者
Matthew T Roe, Paul W Armstrong, Keith AA Fox, Harvey D White, Dorairaj Prabhakaran, Shaun G Goodman, Jan H Cornel, Deepak L Bhatt, Peter Clemmensen, Felipe Martinez, Diego Ardissino, Jose C Nicolau, William E Boden, Paul A Gurbel, Witold Ruzyllo, Anthony J Dalby, Darren K McGuire, Jose L Leiva-Pons, Alexander Parkhomenko, Shmuel Gottlieb, Gracita O Topacio, Christian Hamm, Gregory Pavlides, Assen R Goudev, Ali Oto, Chuen-Den Tseng, Bela Merkely, Vladimir Gasparovic, Ramon Corbalan, Mircea Cinteză, R Craig McLendon, Kenneth J Winters, Eileen B Brown, Yuliya Lokhnygina, Philip E Aylward, Kurt Huber, Judith S Hochman, E Magnus Ohman
发表日期
2012/10/4
期刊
New England journal of medicine
卷号
367
期号
14
页码范围
1297-1309
出版商
Massachusetts Medical Society
简介
Background
The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.
Methods
In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel.
Results
At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05 …
学术搜索中的文章
MT Roe, PW Armstrong, KAA Fox, HD White… - New England journal of medicine, 2012